[1]
|
Möckel, T., Basta, F., Weinmann-Menke, J., et al. (2021) B Cell Activating Factor (BAFF): Structure, Functions, Auto-immunity and Clinical Implications in Systemic Lupus Erythematosus (SLE). Autoimmunity Reviews, 20, Article ID: 102736. https://doi.org/10.1016/j.autrev.2020.102736
|
[2]
|
Yapa, S.W.S., et al. (2016) Comparison of Intravenous and Subcutaneous Exposure Supporting Dose Selection of Subcutaneous Belimumab Systemic Lupus Erythematosus Phase 3 Program. Lupus, 25, 1448-1455.
https://doi.org/10.1177/0961203316642309
|
[3]
|
Struemper, H., Chen, C. and Cai, W. (2013) Population Pharma-cokinetics of Belimumab Following Intravenous Administration in Patients with Systemic Lupus Erythematosus. The Journal of Clinical Pharmacology, 53, 711-720.
https://doi.org/10.1002/jcph.104
|
[4]
|
Zhang, J., Wan, W., Miao, L., et al. (2020) Pharmacokinetics, Pharmacody-namics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. Rheumatology and Therapy, 7, 191-200.
https://doi.org/10.1007/s40744-020-00193-9
|
[5]
|
Yamada, M., Akita, M., Nakagawa, T., et al. (2013) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Belimumab in Japanese Patients with Mild-to-Moderate Sys-temic Lupus Erythematosus. Journal of Drug Assessment, 2, 40-48. https://doi.org/10.3109/21556660.2013.792823
|
[6]
|
Furie, R., Stohl, W., Ginzler, E.M., et al. (2008) Biologic Ac-tivity and Safety of Belimumab, a Neutralizing Anti-B-Lymphocyte Stimulator (BLyS) Monoclonal Antibody: A Phase I Trial in Patients with Systemic Lupus Erythematosus. Arthritis Research & Therapy, 10, R109. http://arthritis-research.com/content/10/5/R109
|
[7]
|
Blair, H.A. and Duggan, S.T. (2018) Belimumab: A Review in Systemic Lupus Erythematosus. Drugs, 78, 355-366.
https://doi.org/10.1007/s40265-018-0872-z
|
[8]
|
Sakai, J. and Akkoyunlu, M. (2017) The Role of BAFF System Molecules in Host Response to Pathogens. Clinical Microbiology Reviews, 30, 991-1014. https://doi.org/10.1128/CMR.00046-17
|
[9]
|
Salazar-Camarena, D.C., et al. (2016) Association of BAFF, APRIL Serum Levels, BAFF-R, TACI and BCMA Expression on Peripheral B-Cell Subsets with Clinical Manifestations in Systemic Lupus Erythematosus. Lupus, 25, 582-592. https://doi.org/10.1177/0961203315608254
|
[10]
|
Gordon, C., Wofsy, D., Wax, S., et al. (2017) Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association between Re-sponse to Atacicept and Serum Biomarkers Including BLyS and APRIL. Arthritis & Rheumatology, 69, 122-130. https://doi.org/10.1002/art.39809
|
[11]
|
Samy, E., Wax, S., Huard, B., et al. (2017) Targeting BAFF and APRIL in Systemic Lupus Erythematosus and Other Antibody-Associated Diseases. International Reviews of Immunology, 36, 3-19.
https://doi.org/10.1080/08830185.2016.1276903
|
[12]
|
Smulski, C.R., Kury, P., Seidel, L.M., et al. (2017) BAFF- and TACI-Dependent Processing of BAFFR by ADAM Proteases Regulates the Survival of B Cells. Cell Reports, 18, 2189-2202. https://doi.org/10.1016/j.celrep.2017.02.005
|
[13]
|
Vincent, F.B., Saulep-Easton, D., Figgett, W.A., et al. (2013) The BAFF/APRIL System: Emerging Functions beyond B Cell Biology and Autoimmunity. Cytokine & Growth Factor Reviews, 24, 203-215.
http://dx.doi.org/10.1016/j.cytogfr.2013.04.003
|
[14]
|
Müller-Winkler, J., Mitter, R., Rappe, J., et al. (2021) Critical Re-quirement for BCR, BAFF, and BAFFR in Memory B Cell Survival. Journal of Experimental Medicine, 218, Article ID: e20191393. https://doi.org/10.1084/jem.20191393
|
[15]
|
Cristian, R. and Smulski, H.E. (2018) BAFF and BAFF-Receptor in B Cell Selection and Survival. Frontiers in Immunology, 9, Article No. 2285. https://doi.org/10.3389/fimmu.2018.02285
|
[16]
|
Katsenelson, N., Kanswal, S., Puig, M., et al. (2007) Synthetic CpG Oligodeoxynucleotides Augment BAFF- and APRIL-Mediated Immunoglobulin Secretion. European Journal of Immunology, 37, 1785-1795.
https://doi.org/10.1002/eji.200636800
|
[17]
|
Sasaki, Y., Casola, S., Kutok, J.L., et al. (2004) TNF Family Member B Cell-Activating Factor (BAFF) Receptor-Dependent and Independent Roles for BAFF in B Cell Physiology. The Journal of Immunology, 173, 2245-2252.
https://doi.org/10.4049/jimmunol.173.4.2245
|
[18]
|
Wise, L.M. and Stohl, W. (2020) Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents. Frontiers in Medicine (Lausanne), 7, Article No. 303. https://doi.org/10.3389/fmed.2020.00303
|
[19]
|
Regola, F., Piantoni, S., Lowin, T., et al. (2019) Associa-tion between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients with Refractory Systemic Lupus Erythematosus Treated with Belimumab. Frontiers in Pharmacology, 10, Article No. 433.
|
[20]
|
(2019) Benlysta Prescribing Information. GlaxoSmithKline, Research Triangle Park.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125370s067,761043s005lbl.pdf
|
[21]
|
European Medi-cines Agency (2017) Benlysta(belimumab): Summary of Product Characteristics.
http://www.ema.europa.eu
|
[22]
|
Rovin, B.H., et al. (2022) A Secondary Analysis of the Belimumab International Study in Lupus Nephritis Trial Examined Effects of Belimumab on Kidney Outcomes and Preservation of Kidney Function in Patients with Lupus Nephritis. Kidney International, 101, 403-413. https://doi.org/10.1016/j.kint.2021.08.027
|
[23]
|
Kiriakidou, M. and Ching, C.L. (2020) Systemic Lupus Erythema-tosus. Annals of Internal Medicine, 172, ITC81-ITC96. https://doi.org/10.7326/AITC202006020
|
[24]
|
Yu, H., Nagafuchi, Y. and Fujio, K. (2021) Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. Biomol-ecules, 11, Article No. 928. https://doi.org/10.3390/biom11070928
|
[25]
|
Zhang, F., Bae, S.C., Bass, D., et al. (2018) A Pivotal Phase III, Randomised, Placebo-Controlled Study of Belimumab in Patients with Systemic Lupus Ery-thematosus Located in China, Japan and South Korea. Clinical and Epidemiological Research, 77, 355-363. https://doi.org/10.1136/annrheumdis-2017-211631
|
[26]
|
Navarra, S.V., et al. (2011) Efficacy and Safety of Belimumab in Patients with Active Systemic Lupus Erythematosus: A Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, 377, 721-731.
https://doi.org/10.1016/S0140-6736(10)61354-2
|
[27]
|
Furie, R., Petri, M., Zamani, O., et al. (2011) A Phase III, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits B Lymphocyte Stimulator, in Patients with Systemic Lupus Erythematosus. Arthritis & Rheumatism, 63, 3918-3930. https://doi.org/10.1002/art.30613
|
[28]
|
Oon, S., Huq, M., Godfrey, T., et al. (2018) Systematic Review, and Me-ta-Analysis of Steroid-Sparing Effect, of Biologic Agents in Randomized, Placebo-Controlled Phase 3 Trials for System-ic Lupus Erythematosus. Seminars in Arthritis and Rheumatism, 48, 221-239. https://doi.org/10.1016/j.semarthrit.2018.01.001
|
[29]
|
von Kempis, J., Duetsch, S., Reuschling, N., et al. (2019) Clinical Outcomes in Patients with Systemic Lupus Erythematosus Treated with Belimumab in Clinical Practice Settings: A Retrospective Analysis of Results from the OBSErve Study in Switzerland. Swiss Medical Weekly, 149, w20022. https://doi.org/10.4414/smw.2019.20022
|
[30]
|
Schwartzman-Morris, J. and Putterman, C. (2012) Gender Differ-ences in the Pathogenesis and Outcome of Lupus and of Lupus Nephritis. Clinical and Developmental Immunology, 2012, Article ID 604892.
https://doi.org/10.1155/2012/604892
|
[31]
|
Shao, S.J., Hou, J.H., Xie, G.T., et al. (2019) Improvement of Out-comes in Patients with Lupus Nephritis: Management Evolution in Chinese Patients from 1994 to 2010. The Journal of Rheumatology, 46, 912-919.
https://doi.org/10.3899/jrheum.180145
|
[32]
|
Tran, N.L., Schneider, P. and Santiago-Raber, M.L. (2017) TACI-Dependent APRIL Signaling Maintains Autoreactive B Cells in a Mouse Model of Systemic Lupus Erythematosus. European Journal of Immunology, 47, 713-723.
https://doi.org/10.1002/eji.201646630
|
[33]
|
Sciascia, S., Radin, M., Yazdany, J., et al. (2017) Efficacy of Belimumab on Renal Outcomes in Patients with Systemic Lupus Erythematosus: A Systematic Review. Autoimmunity Reviews, 16, 287-293.
https://doi.org/10.1016/j.autrev.2017.01.010
|
[34]
|
Furie, B.H.R., et al. (2020) OP0164 BLISS-LN: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial of Intravenous Belimumab in Patients with Active Lupus Nephritis. An-nals of the Rheumatic Diseases, 79, Article No. 103. https://doi.org/10.1136/annrheumdis-2020-eular.3881
|
[35]
|
Manfrè, V., Chatzis, L.G., Cafaro, G., et al. (2022) Sjögren’s Syndrome: One Year in Review 2022. Clinical and Experimental Rheumatology, 40, 2211-2224. https://doi.org/10.55563/clinexprheumatol/43z8gu
|
[36]
|
Xavier Mariette, R.S., Luca Quartuccio, G.B., Sara Salvin, M.F., et al. (2015) Efficacy and Safety of Belimumab in Primary Sjögren’s Syndrome: Results of the BELISS Open-Label Phase II Study. Annals of the Rheumatic Diseases, 74, 526-531. https://doi.org/10.1136/annrheumdis-2013-203991
|
[37]
|
De Vita, S., Quartuccio, L., Seror, R., et al. (2015) Effi-cacy and Safety of Belimumab Given for 12 Months in Primary Sjögren’s Syndrome: The BELISS Open-Label Phase II Study. Rheumatology (Oxford), 54, 2249-2256.
https://doi.org/10.1093/rheumatology/kev257
|
[38]
|
Ramos-Casals, M., Brito-Zerón, P., Bombardieri, S., et al. (2020) EULAR Recommendations for the Management of Sjögren’s Syndrome with Topical and Systemic Therapies. Annals of the Rheumatic Diseases, 79, 3-18.
https://doi.org/10.1136/annrheumdis-2019-216114
|
[39]
|
Saviana Gandolfo, S.D.V. (2019) Double Anti-B Cell and Anti-BAFF Targeting for the Treatment of Primary Sjögren’s Syndrome. Clinical and Experimental Rheumatology, 118, 199-208.
|
[40]
|
Mariette, X., Barone, F., Baldini, C., et al. (2022) A Randomized, Phase II Study of Sequential Belimumab and Rituximab in Primary Sjögren’s Syndrome. JCI Insight, 7, e163030. https://doi.org/10.1172/jci.insight.163030
|
[41]
|
Sammaritano, L.R. (2020) Antiphospholipid Syndrome. Best Prac-tice & Research Clinical Rheumatology, 34, Article ID: 101463. https://doi.org/10.1016/j.berh.2019.101463
|
[42]
|
Yazici, B.Y. and Erkan, D. (2017) Belimumab in Primary An-tiphospholipid Syndrome. Lupus, 26, 1123-1124.
https://doi.org/10.1177/0961203316682102
|
[43]
|
Emmi, G., Bettiol, A., Palterer, B., et al. (2019) Belimumab Re-duces Antiphospholipid Antibodies in SLE Patients Independently of Hydroxychloroquine Treatment. Autoimmunity Re-views, 18, 312-314.
https://doi.org/10.1016/j.autrev.2018.11.002
|
[44]
|
Stohl, W., Hiepe, F., Latinis, K.M., et al. (2012) Belimumab Reduces Autoantibodies, Normalizes Low Complement Levels, and Reduces Select B Cell Populations in Patients with Systemic Lupus Erythematosus. Arthritis & Rheumatism, 64, 2328-2237. https://doi.org/10.1002/art.34400
|
[45]
|
van den Hoogen, L.L., Palla, G., Bekker, C., et al. (2018) Increased B-Cell Activating Factor (BAFF)/B-Lymphocyte Stimulator (BLyS) in Primary Antiphospholipid Syndrome Is Associated with Higher Adjusted Global Antiphospholipid Syndrome Scores. RMD Open, 4, e000693. https://doi.org/10.1136/rmdopen-2018-000693
|
[46]
|
Yoshizuka, R., Hasegawa, H., Kamiya, M., et al. (2022) Re-fractory Antiphospholipid Antibody Syndrome-Induced Thrombocytopaenia Successfully Treated with Belimumab. Lu-pus, 31, 624-627.
https://doi.org/10.1177/09612033221089138
|
[47]
|
Maxime Beydon, S.M., Yann Nguyen, T.S. and Xavier Mariette, R.S. (2023) Epidemiology of Sjögren Syndrome. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-023-01057-6
|
[48]
|
Wu, M. and Mohan, C. (2015) B-Cells in Systemic Sclerosis: Emerging Evidence from Genetics to Phenotypes. Current Opinion in Rheumatology, 27, 537-541.
|
[49]
|
Sakkas, L.I. and Bogdanos, D.P. (2016) Systemic Sclerosis: New Evidence Re-Enforces the Role of B Cells. Autoimmunity Reviews, 15, 155-161. http://dx.doi.org/10.1016/j.autrev.2015.10.005
|
[50]
|
Matsushita, T., Hasegawa, M., Yanaba, K., et al. (2006) Elevated Serum BAFF Levels in Patients with Systemic Sclerosis: Enhanced BAFF Signaling in Systemic Sclerosis B Lymphocytes. Arthritis & Rheumatism, 54, 192-201.
https://doi.org/10.1002/art.21526
|
[51]
|
Mwangi, J., Litteken, C., Gorthi, R., et al. (2021) Belimumab in the Treat-ment of Connective Tissue Disease-Associated Interstitial Lung Disease: Case Report and Literature Review. Cureus, 13, e19218.
|
[52]
|
Mami Hara, M.O., Yoshinao Muro, T.T. and Akiyama, M. (2020) A Case of Systemic Lupus Erythema-tosus/Systemic Sclerosis Overlap Syndrome Successfully Treated with Belimumab. European Journal of Dermatology, 30, 615-617.
|
[53]
|
Gordon, J.K., Martyanov, V., Franks, J.M., et al. (2018) Belimumab for the Treatment of Early Dif-fuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. Arthritis and Rheuma-tology, 70, 308-316. https://doi.org/10.1002/art.40358
|
[54]
|
Lundberg, I.E., Fujimoto, M., Vencovsky, J., et al. (2021) Idiopathic Inflammatory Myopathies. Nature Reviews Disease Primers, 7, Article No. 86. https://doi.org/10.1038/s41572-021-00325-7
|
[55]
|
Kryštůfková, O., Barbasso Helmers, S., Venalis, P., et al. (2014) Expression of BAFF Receptors in Muscle Tissue of Myositis Patients with Anti-Jo-1 or Anti-Ro52/Anti-Ro60 Autoan-tibodies. Arthritis Research and Therapy, 16, Article No. 454.
|
[56]
|
Baek, A., Park, H.J., Na, S.J., et al. (2012) The Ex-pression of BAFF in the Muscles of Patients with Dermatomyositis. Journal of Neuroimmunology, 249, 96-100. https://doi.org/10.1016/j.jneuroim.2012.04.006
|
[57]
|
Cui, B.B., Tian, Y.R., Ma, X.Y., et al. (2021) Belimumab for Immune-Mediated Necrotizing Myopathy Associated with Anti-SRP Antibodies: A Case Report and Retrospective Re-view of Patients Treated with Anti-B-Cell Therapy in a Single Center and Literature. Frontiers in Immunology, 12, Arti-cle ID: 777502.
https://doi.org/10.3389/fimmu.2021.777502
|
[58]
|
Marder, G., Quach, T., Chadha, P., et al. (2023) Belimumab Treatment of Adult Idiopathic Inflammatory Myopathy. Rheumatology (Oxford), 2023, kead281. https://doi.org/10.1093/rheumatology/kead281
|
[59]
|
Radu, A.F. and Bungau, S.G. (2021) Management of Rheu-matoid Arthritis: An Overview. Cells, 10, Article No. 2857.
https://doi.org/10.3390/cells10112857
|
[60]
|
Stohl, W., Merrill, J.T., McKay, J.D., et al. (2013) Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study. The Journal of Rheumatology, 40, 579-589. https://doi.org/10.3899/jrheum.120886
|
[61]
|
Komori, A. (2021) Recent Updates on the Management of Autoim-mune Hepatitis. Clinical and Molecular Hepatology, 27, 58-69. https://doi.org/10.3350/cmh.2020.0189
|
[62]
|
Ar-vaniti, P., Giannoulis, G., Gabeta, S., et al. (2020) Belimumab Is a Promising Third-Line Treatment Option for Refracto-ry Autoimmune Hepatitis. JHEP Reports, 2, Article No. 100123. https://doi.org/10.1016/j.jhepr.2020.100123
|
[63]
|
Lanzillotta, M., Mancuso, G. and Della-Torre, E. (2020) Ad-vances in the Diagnosis and Management of IgG4 Related Disease. BMJ, 369, m1067. https://doi.org/10.1136/bmj.m1067
|
[64]
|
Yamamoto, M., Aochi, S., Suzuki, C., et al. (2019) A Case with Good Response to Belimumab for Lupus Nephritis Complicated by IgG4-Related Disease. Lupus, 28, 786-789. https://doi.org/10.1177/0961203319840430
|
[65]
|
Katayama, Y., Katsuyama, T., Shidahara, K., et al. (2022) A Case of Recurrent IgG4-Related Disease Successfully Treated with Belimumab after Remission of Systemic Lupus Erythema-tosus. Rheumatology (Oxford), 61, e308-e310.
https://doi.org/10.1093/rheumatology/keac284
|
[66]
|
Anjo, C., Mascaró, J.M., Espinosa, G., et al. (2019) Effective-ness and Safety of Belimumab in Patients with Systemic Lupus Erythematosus in a Real-World Setting. Scandinavian Journal of Rheumatology, 48, 469-473.
https://doi.org/10.1080/03009742.2019.1603324
|
[67]
|
谢文慧, 张卓莉. 贝利尤单抗治疗系统性红斑狼疮: 现状与展望[J]. 中华风湿病学杂志, 2020, 24(7): 495-499.
|
[68]
|
Fredericks, C.A., et al. (2014) A Case of Progressive Multifocal Leukoencephalopathy in a Lupus Patient Treated with Belimumab. Lupus, 23, 711-713. https://doi.org/10.1177/0961203314524292
|
[69]
|
Yang, H., Liu, H., Zhou, Z., et al. (2021) Management of Severe Refractory Systemic Lupus Erythematosus: Real-World Experience and Literature Review. Clinical Reviews in Allergy and Immunology, 60, 17-30.
https://doi.org/10.1007/s12016-020-08817-2
|
[70]
|
Kaegi, C., et al. (2021) Systematic Review of Safety and Effi-cacy of Belimumab in Treating Immune-Mediated Disorders. Allergy, 76, 2673-2683. https://doi.org/10.1111/all.14704
|